Advertisement

Allergo Journal

, Volume 28, Issue 1, pp 31–47 | Cite as

Leitlinie: Hereditäres Angioödem durch C1-Inhibitor-Mangel

S1-Leitlinie der Deutschen Gesellschaft für Angioödeme (DGA), der Deutschen Gesellschaft für Innere Medizin (DGIM), der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde (DGHNO), der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ), der Deutschen Dermatologischen Gesellschaft (DDG), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), des Deutschen Berufsverbands der Hals-Nasen-Ohren-Ärzte (BVHNO) und der HAE-Vereinigung (HAE-SHG)
  • Konrad BorkEmail author
  • Emel Aygören-Pürsün
  • Murat Bas
  • Tilo Biedermann
  • Jens Greve
  • Karin Hartmann
  • Markus Magerl
  • Inmaculada Martinez-Saguer
  • Marcus Maurer
  • Hagen Ott
  • Lucia Schauf
  • Petra Staubach
  • Bettina Wedi
Leitlinie
  • 93 Downloads

Ziel der Leitlinie

Diese Leitlinie beruht auf dem informellen Konsensus von Experten, die sich in Deutschland seit langer Zeit mit Patienten mit hereditärem Angioödem (HAE) aufgrund eines genetischen C1-Inhibitor(C1-INH)-Mangels (HAE-C1-INH) befassen, und einer nicht systematischen Literaturrecherche. Die Leitlinie ist ein Update der bisherigen AWMF-Leitlinie „Hereditäres Angioödem durch C1-Inhibitor-Mangel“ aus dem Jahr 2012. Aufgenommen wurden neue Entwicklungen auf diesem Gebiet unter Berücksichtigung der zwischen 2012 und 2018 erschienenen Publikationen, sofern sie für die Leitlinie relevant waren. Weiterhin wurden verschiedene Konsensusarbeiten und Leitlinien berücksichtigt, darunter auch das Update von 2017 der WAO/EAACI-Leitlinie (World Allergy Organization/The European Academy of Allergy and Clinical Immunology) zur Behandlung des HAE [1, 2, 3, 4].

Die Leitlinie richtet sich in erster Linie an Ärzte, die Patienten mit HAE-C1-INH behandeln. Dies sind in Deutschland meist...

Schlüsselwörter

Hereditäres Angioödem C1-Inhibitor Mangel Akuttherapie Prophylaxe praktische Maßnahmen 

Abkürzungen

ACE

Angiotensin converting enzyme

C1-INH

C1-Esterase-Inhibitor

EACA

Epsilonaminocapronsäure

GFP

gefrorenes Frischplasma

HAE

Hereditäres Angioödem

IE

Internationale Einheit

IgE

Immunglobulin E

KKS

Kallikrein-Kinin-System

rh

rekombinant human

Literatur

  1. 1.
    Betschel S, Badiou J, Binkley K, Hébert J, Kanani A, Keith P et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 2014;10:50CrossRefGoogle Scholar
  2. 2.
    Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67:147–57CrossRefGoogle Scholar
  3. 3.
    Maurer M, Magerl M, Ansotegui I, Aygören Pürsün E, Betschel S, Bork K et al. The international WAO/EAACI guideline for the management of hereditary angioedema–The 2017 revision and update. Allergy 2018;73:1575–96CrossRefGoogle Scholar
  4. 4.
    Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017;72:300–13CrossRefGoogle Scholar
  5. 5.
    Bork K. Angioedema. Immunol Allergy Clin North Am 2014;34:23–31CrossRefGoogle Scholar
  6. 6.
    Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis 2018;13:73CrossRefGoogle Scholar
  7. 7.
    Gösswein T, Kocot A, Emmert G, Kreuz W, Martinez-Saguer I, Aygören-Pürsün E et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 2008;121:181–8CrossRefGoogle Scholar
  8. 8.
    Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 2008;45:3536–44CrossRefGoogle Scholar
  9. 9.
    Germenis AE, Speletas M. Genetics of Hereditary Angioedema Revisited. Clin Rev Allergy Immunol 2016;51:170–82CrossRefGoogle Scholar
  10. 10.
    Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693–7CrossRefGoogle Scholar
  11. 11.
    Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999;104:1321–2CrossRefGoogle Scholar
  12. 12.
    Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109:1057–63CrossRefGoogle Scholar
  13. 13.
    Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119:1497–503CrossRefGoogle Scholar
  14. 14.
    Göring HD, Bork K, Späth PJ, Bauer R, Ziemer A, Hintner H et al. Untersuchungen zum hereditären Angioödem im deutschsprachigen Raum. Hautarzt 1998;49:114–22CrossRefGoogle Scholar
  15. 15.
    Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006;101:619–27CrossRefGoogle Scholar
  16. 16.
    Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003;163:1229–35CrossRefGoogle Scholar
  17. 17.
    Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci 2003;29:235–8CrossRefGoogle Scholar
  18. 18.
    Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000;75:349–54CrossRefGoogle Scholar
  19. 19.
    Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 2003;134:1088–94CrossRefGoogle Scholar
  20. 20.
    Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012;130:692–7CrossRefGoogle Scholar
  21. 21.
    Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267–74CrossRefGoogle Scholar
  22. 22.
    Czaller I, Visy B, Csuka D, Füst G, Tóth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol 2010;152:44–9CrossRefGoogle Scholar
  23. 23.
    Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010;203:131.e1–7CrossRefGoogle Scholar
  24. 24.
    Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:58–64CrossRefGoogle Scholar
  25. 25.
    Aygören-Pürsün E, Martinez Saguer I, Kreuz W, Klingebiel T, Schwabe D. Risk of angioedema following invasive or surgical procedures in HAE type I and II–the natural history. Allergy 2013;68:1034–9CrossRefGoogle Scholar
  26. 26.
    Böckers M, Bork K. Kontrazeption und Schwangerschaft beim hereditären Angioödem. Dtsch Med Wochenschr 1987;112:507–9CrossRefGoogle Scholar
  27. 27.
    Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003;114:294–8CrossRefGoogle Scholar
  28. 28.
    Bork K, Wulff K, Steinmüller-Magin L, Braenne I, Staubach-Renz P, Witzke G et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018;73:442–50CrossRefGoogle Scholar
  29. 29.
    Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009;124:129–34CrossRefGoogle Scholar
  30. 30.
    Bafunno V, Firinu D, D’Apolito M, Cordisco G, Loffredo S, Leccese A et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018;141:1009–17CrossRefGoogle Scholar
  31. 31.
    Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005;45:1774–84CrossRefGoogle Scholar
  32. 32.
    Craig TJ, Rojavin MA, Machnig T, Keinecke HO, Bernstein JA. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol 2013;111:211–5CrossRefGoogle Scholar
  33. 33.
    Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013;8:e53773CrossRefGoogle Scholar
  34. 34.
    Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions. Expert Rev Clin Immunol 2008;4:13–20CrossRefGoogle Scholar
  35. 35.
    Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001;161:714–8CrossRefGoogle Scholar
  36. 36.
    Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008;63:751–7CrossRefGoogle Scholar
  37. 37.
    Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124:801–8CrossRefGoogle Scholar
  38. 38.
    Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009;49:1987–95CrossRefGoogle Scholar
  39. 39.
    Farkas H, Jakab L, Temesszentandrási G, Visy B, Harmat G, Füst G et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007;120:941–7CrossRefGoogle Scholar
  40. 40.
    Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 2009;122:780–3CrossRefGoogle Scholar
  41. 41.
    Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011;154:81–8CrossRefGoogle Scholar
  42. 42.
    Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations and treatment. Br J Hosp Med (Lond) 2006;67:654–7CrossRefGoogle Scholar
  43. 43.
    Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532–41CrossRefGoogle Scholar
  44. 44.
    Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011;107:529–37CrossRefGoogle Scholar
  45. 45.
    Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;126:821–7.e14CrossRefGoogle Scholar
  46. 46.
    Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 2014;112:163–9.e1CrossRefGoogle Scholar
  47. 47.
    Reshef A, Moldovan D, Obtulowicz K, Leibovich I, Mihaly E, Visscher S et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 2013;68:118–24CrossRefGoogle Scholar
  48. 48.
    Moldovan D, Reshef A, Fabiani J, Kivity S, Toubi E, Shlesinger M et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012;42:929–35CrossRefGoogle Scholar
  49. 49.
    Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007;98:383–8CrossRefGoogle Scholar
  50. 50.
    Kaminsky LW, Kelbel T, Ansary F, Craig T. Multiple doses of icatibant used during pregnancy. Allergy Rhinol (Providence) 2017;8:178–81CrossRefGoogle Scholar
  51. 51.
    Farkas H, Kohalmi KV, Veszeli N, Tóth F, Varga L. First report of icatibant treatment in a pregnant patient with hereditary angioedema. J Obstet Gynaecol Res 2016;42:1026–8CrossRefGoogle Scholar
  52. 52.
    Zanichelli A, Mansi M, Periti G. Icatibant Exposure During Pregnancy in a Patient With Hereditary Angioedema. J Investig Allergol Clin Immunol 2015;25:447–9PubMedGoogle Scholar
  53. 53.
    Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. J Allergy Clin Immunol Pract 2017;5:1671–8.e2CrossRefGoogle Scholar
  54. 54.
    Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989;83:677–82CrossRefGoogle Scholar
  55. 55.
    Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334:1630–4CrossRefGoogle Scholar
  56. 56.
    Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006;117:904–8CrossRefGoogle Scholar
  57. 57.
    Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513–22CrossRefGoogle Scholar
  58. 58.
    Bork K. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE). Clin Rev Allergy Immunol 2016;51:183–92CrossRefGoogle Scholar
  59. 59.
    Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295:1444–8PubMedGoogle Scholar
  60. 60.
    Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153–61CrossRefGoogle Scholar
  61. 61.
    Füst G, Farkas H, Csuka D, Varga L, Bork K. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011;41:256–62CrossRefGoogle Scholar
  62. 62.
    Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril 1990;54:64–72CrossRefGoogle Scholar
  63. 63.
    Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99:194–6CrossRefGoogle Scholar
  64. 64.
    Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002;36:707–9CrossRefGoogle Scholar
  65. 65.
    Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999;353:1066–7CrossRefGoogle Scholar
  66. 66.
    Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972;286:808–12CrossRefGoogle Scholar
  67. 67.
    Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972;287:452–4CrossRefGoogle Scholar
  68. 68.
    Blohmé G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand 1972;192:293–8PubMedGoogle Scholar
  69. 69.
    Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008;199:484.e1–4CrossRefGoogle Scholar
  70. 70.
    Saule C, Boccon-Gibod I, Fain O, Kanny G, Plu-Bureau G, Martin L et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy 2013;43:475–82CrossRefGoogle Scholar
  71. 71.
    Longhurst HJ. Hereditary and other orphan angioedemas: a new prophylactic option at last? Clin Exp Allergy 2013;43:380–2CrossRefGoogle Scholar
  72. 72.
    Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med 2017;376:1131–40CrossRefGoogle Scholar
  73. 73.
    Banerji A, Busse P, Shennak M, Lumry W, Davis-Lorton M, Wedner HJ et al. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. N Engl J Med 2017;376:717–28CrossRefGoogle Scholar
  74. 74.
    Aygören-Pürsün E, Bygum A, Grivcheva-Panovska V, Magerl M, Graff J, Steiner UC et al. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. N Engl J Med 2018;379:352–62CrossRefGoogle Scholar
  75. 75.
    Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S et al. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis 2014;9:99CrossRefGoogle Scholar
  76. 76.
    Caballero T, Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc 2014;35:47–53CrossRefGoogle Scholar
  77. 77.
    Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010;31:407–14CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Konrad Bork
    • 1
    Email author
  • Emel Aygören-Pürsün
    • 2
  • Murat Bas
    • 3
  • Tilo Biedermann
    • 4
  • Jens Greve
    • 5
  • Karin Hartmann
    • 6
  • Markus Magerl
    • 7
  • Inmaculada Martinez-Saguer
    • 8
  • Marcus Maurer
    • 7
  • Hagen Ott
    • 9
  • Lucia Schauf
    • 10
  • Petra Staubach
    • 1
  • Bettina Wedi
    • 11
  1. 1.HautklinikUniversitätsmedizin MainzMainzDeutschland
  2. 2.Klinik für Kinder- und JugendmedizinUniversitätsklinikum FrankfurtFrankfurtDeutschland
  3. 3.OttobrunnDeutschland
  4. 4.Hautklinik Campus BiedersteinTechnische Universität MünchenMünchenDeutschland
  5. 5.Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und HalschirurgieUniversitätsklinikum UlmUlmDeutschland
  6. 6.Klinik für Dermatologie und VenerologieUniversitätsklinikum Schleswig-HolsteinLübeckDeutschland
  7. 7.Klinik für Dermatologie, Allergologie und VenerologieCharité — UniversitätsmedizinBerlinDeutschland
  8. 8.Hämophilie-Zentrum Rhein-MainMörfelden-WalldorfDeutschland
  9. 9.Auf der Bult, Fachbereich Pädiatrische Dermatologie und AllergologieHannoverDeutschland
  10. 10.HAE-Vereinigung, SelbsthilfegruppeAldenhovenDeutschland
  11. 11.Klinik für Dermatologie, Allergologie und VenerologieMedizinische Hochschule HannoverHannoverDeutschland

Personalised recommendations